Back to Search Start Over

Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study.

Authors :
Le Borgne, Pierrick
Feuillassier, Léa
Schenck, Maleka
Herbrecht, Jean-Etienne
Janssen-Langenstein, Ralf
Simand, Celestine
Gantzer, Justine
Nannini, Simon
Fornecker, Luc-Matthieu
Alamé, Karine
Lefebvre, François
Castelain, Vincent
Schneider, Francis
Clere-Jehl, Raphaël
Source :
Cancers; Jul2022, Vol. 14 Issue 13, pN.PAG-N.PAG, 12p
Publication Year :
2022

Abstract

Simple Summary: Patients with malignancies (solid tumors or hematological diseases) are at high risk of developing sepsis and are increasingly admitted to ICU due to their long-term prognosis improvement. The main objective of this study was to compare the short- and long-term prognoses of patients with and without cancer admitted to the ICU for septic shock. In-hospital and ICU mortality, as well as LOS, were not different in SSh patients with and without cancer, suggesting that malignancies should no longer be considered a barrier to ICU admission. Introduction: Cancer patients are at high risk of developing septic shock (SSh) and are increasingly admitted to ICU given their improved long-term prognosis. We, therefore, compared the prognosis of cancer and non-cancer patients with SSh. Methods: We conducted a monocentric, retrospective cohort study (2013–2019) on patients admitted to ICU for SSh. We compared the clinical characteristics and management and studied short- and long-term mortality with ICU and in-hospital mortality and 1-year survival according to cancer status. Results: We analyzed 239 ICU stays in 210 patients, 59.5% of whom were men (n = 125), with a median age of 66.5 (IQR 56.3–77.0). Of the 121 cancer patients (57.6% of all patients), 70 had solid tumors (33.3%), and 51 had hematological malignancies (24.3%). When comparing ICU stays of patients with versus without cancer (n = 148 vs. n = 91 stays, respectively), mortality reached 30.4% (n = 45) vs. 30.0% (n = 27) in the ICU (p = 0.95), and 41.6% (n = 59) vs. 35.6% (n = 32) in hospital (p = 0.36), respectively. ICU length of stay (LOS) was 5.0 (2.0–11.3) vs. 6.0 (3.0–15.0) days (p = 0.27), whereas in-hospital LOS was 25.5 (13.8–42.0) vs. 19.5 (10.8–41.0) days (p = 0.33). Upon multivariate analysis, renal replacement therapy (OR = 2.29, CI95%: 1.06–4.93, p = 0.03), disseminated intravascular coagulation (OR = 5.89, CI95%: 2.49–13.92, p < 0.01), and mechanical ventilation (OR = 7.85, CI95%: 2.90–21.20, p < 0.01) were associated with ICU mortality, whereas malignancy, hematological, or solid tumors were not (OR = 1.41, CI95%: 0.65–3.04; p = 0.38). Similarly, overall cancer status was not associated with in-hospital mortality (OR = 1.99, CI95%: 0.98–4.03, p = 0.06); however, solid cancers were associated with increased in-hospital mortality (OR = 2.52, CI95%: 1.12–5.67, p = 0.03). Lastly, mortality was not significantly different at 365-day follow-up between patients with and without cancer. Conclusions: In-hospital and ICU mortality, as well as LOS, were not different in SSh patients with and without cancer, suggesting that malignancies should no longer be considered a barrier to ICU admission. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20726694
Volume :
14
Issue :
13
Database :
Complementary Index
Journal :
Cancers
Publication Type :
Academic Journal
Accession number :
157914416
Full Text :
https://doi.org/10.3390/cancers14133196